Kovack Advisors Inc. Increases Stake in Pfizer Inc. $PFE

Kovack Advisors Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 80.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 143,951 shares of the biopharmaceutical company’s stock after buying an additional 64,044 shares during the quarter. Kovack Advisors Inc.’s holdings in Pfizer were worth $3,584,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Horizon Financial Services LLC increased its stake in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer during the 4th quarter valued at approximately $26,000. YANKCOM Partnership purchased a new position in shares of Pfizer in the fourth quarter valued at $28,000. HFM Investment Advisors LLC increased its position in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Darwin Wealth Management LLC bought a new stake in Pfizer in the second quarter worth $32,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on PFE. HSBC increased their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Barclays assumed coverage on shares of Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. Bank of America reduced their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.82.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded HYMPAVZI’s U.S. indication to include more hemophilia A and B patients, including pediatric use, improving Pfizer’s rare-disease growth outlook and potentially boosting future sales. Pfizer shares climb 3.2% as investors digest expanded U.S. label for HYMPAVZI
• Positive Sentiment: RBC Capital Markets upgraded Pfizer to Sector Perform, saying the stock’s recent weakness has improved the risk-reward profile and reset valuation ahead of key pipeline catalysts. Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts
• Positive Sentiment: Multiple articles highlighted Pfizer’s obesity, oncology, and pneumococcal pipeline updates, signaling continued investment in new growth drivers beyond COVID-era revenues. Pfizer’s New Phase 1 PF-07799544 Study Adds Quiet Depth to Its R&D Pipeline
• Neutral Sentiment: Articles discussing Pfizer’s dividend yield and whether the stock is a buy or hold are mostly commentary, but they reinforce investor interest in PFE as an income name. A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
• Negative Sentiment: Pfizer’s CEO warned that planned investment in Germany could be reconsidered because of proposed drug-pricing changes, underscoring ongoing policy risk for the company. Pfizer CEO warns German investment at risk over drug pricing policies

Pfizer Price Performance

PFE stock opened at $26.17 on Friday. The stock has a market cap of $149.15 billion, a PE ratio of 19.98 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The company has a 50-day moving average price of $26.48 and a 200 day moving average price of $26.32. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter last year, the firm earned $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.